Filter posts

FDA Week: For Biologics, A Name Isn't Just A Name (Jim Greenwood op-ed)

What is in a name? Names help make medicinal products more easily distinguishable by doctors, …

Stable Policy Can Help Assure Unwavering Investment in U.S. Biofuels

The Renewable Fuel Standard (RFS) is a unique federal policy that has, just as its …

Congress Passes Omnibus Spending Agreement

This week, BIO President and CEO Jim Greenwood praised the Congress for passing the fundingbill …

BIO Joins Partners for Healthy Dialogues

The Biotechnology Industry Organization (BIO) recently joined the Partners for Healthy Dialogues effort. Dialogues+ had …

BIO President & CEO Presents Dr. Cohen With Lifetime Achievement Award

Last week, Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), attended the …

A Manhattan Project for Alzheimer's Disease

Earlier this month, at the Alzheimer’s Disease Summit in New York City, BIO‘s President & …

UK Bioscience Forum: Confronting Common Challenges

This week, BIO’s President and CEO Jim Greenwood delivered a plenary address to attendees at …

Ask CA Governor Brown To Sign SB 598

California’s Assembly and Senate have both overwhelmingly passed Senate Bill 598, legislation that creates a …

BIO Welcomes Five New Board Members

BIO elected five new members to its Board of Directors, voted upon at this year’s …

State Legislation Needed For Substitution of Interchangeable Biologics

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to …